Noninvasive preimplantation genetic testing for aneuploidy in spent blastocyst media will substitute for trophectoderm biopsy
VOLUME 115, ISSUE 4, P840
Carlos Simon, M.D., Ph.D.
The discovery of cell-free fetal deoxyribonucleic acid in maternal plasma has enabled a paradigm shift in prenatal testing (1). Since its inception, noninvasive prenatal testing (niPGT) has dramatically changed clinical practice in prenatal care, allowing safer and earlier detection of genetic conditions of the fetus during the first trimester of pregnancy (2).